Corporate Compliance

Medical testing company will pay $302M to settle false marketing case

Compliance Monitor, April 22, 2009

Quest Diagnostics will pay $302 million to settle civil charges of misleading marketing and criminal charges of misbranding, according to a Department of Justice (DOJ) release.
Quest also entered into a corporate integrity agreement with the OIG as part of the settlement.
The settlement resolves allegations that Quest and its subsidiary company, Nichols Institute Diagnostics, knowingly marketed a diagnostic test kit, used to measure parathyroid hormone levels in patients, as being more accurate than is actually was, according to the DOJ.

Most Popular